No Data
No Data
Dimerix (ASX:DXB) Shareholders Have Earned a 359% Return Over the Last Year
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication
Dimerix (ASX:DXB) secured approval from the UK Medicines and Healthcare Products Regulatory Agency for the pediatric investigation plan for its kidney disease medication DMX-200, according to a Wednes
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter
Dimerix (ASX:DXB) has reported AU$35.2 million in cash and AU$3.3 million of operating cash outflows for the quarter ended March 31, mostly from clinical and CMC costs related to its Phase 3 FSGS stud
Dimerix Initiated at A$0.80/Share Price Target by Euroz Hartleys
Dimerix Initiated at A$0.80/Share Price Target by Euroz Hartleys
Dimerix With Proactive at ASX Small and Mid Cap Conference | ASX:DXB, OTC:SBMJF
Dimerix Raises AU$20 Million for Kidney Disease Study
Dimerix (ASX:DXB) raised AU$20 million via an institutional placement of 66,666,667 ordinary shares at AU$0.30 apiece. Proceeds will be used to complete the ACTION3 phase three clinical study in patie
No Data